News
Vektor Medical Initiates IMPRoVED AF Post-Market Clinical Study Evaluating the Impact of vMap in Ablating Non-Pulmonary Vein AF Drivers
Vektor Medical is excited to announce the launch of IMPRoVED AF, a prospective, randomized, controlled, multi-center clinical trial evaluating the benefits of AI-guided mapping in the treatment of persistent and recurrent atrial fibrillation (AF). The study will assess how vMap - Vektor’s FDA-cleared, non-invasive arrhythmia analysis platform - can enhance outcomes by identifying and targeting electrical drivers outside the pulmonary veins.
The study will enroll up to 384 patients across up-to 15 EP centers in the U.S. and Europe. All enrolled patients will undergo a standard 12-lead ECG. Those randomized to the intervention arm will receive additional targeted ablation based on vMap's analysis of non-pulmonary vein drivers.
The primary endpoint is freedom from AF at 12 months, with or without antiarrhythmic drugs.
Key secondary endpoints include:
- Freedom from AF and atrial tachycardia (AT) at 12 months
- Total procedure and vMap mapping time
- Change in AF burden post-ablation
- Rate of spontaneous AF termination during ablation
- Total fluoroscopy exposure
Vektor Medical, Inc. Chosen as a San Diego Venture Group 2020 Cool Company
Vektor has been selected as one of San Diego Venture Group’s ‘Cool Companies’ for 2020. Connect w/ San Diego Venture Group (SDVG) promotes the formation, funding, and development of innovative new ventures in the San Diego community. "We help innovative companies thrive so they can make a meaningful impact on the economic development of the region, and together create a world-class tech ecosystem," Mike Krenn, CEO of Connect. SDVG’s Cool Companies list highlights the fastest-growing, most exciting startups in Southern California.
Computer-Based 12-Lead ECG Analysis Accurately Maps Ventricular Locations
Researchers, in an abstract and associated poster published in the Heart Rhythm Society’s journal Heart Rhythm, find that computer-based analysis of 12-lead ECG accurately mapped 93% of known ventricular locations to the exact ventricular segment. The computer-based analysis required only 3 minutes, plus or minus 2 minutes, per ECG.
Vektor Medical, Inc. Announces the Closing of Its Series Seed Funding Round to Support the Development and U.S. FDA Clearance of vMap™
Vektor Medical, Inc. is pleased to announce its Series Seed financing round is fully subscribed, and the round is officially closed. The investment round will enable Vektor to further invest in investigative research, efforts toward U.S. Food and Drug Administration 510(K) clearance, and development of a commercial product. “With the support of our investors, we are delighted to have successfully closed this funding round in less than two months and with more investor interest than we had room for in the round.” Rob Krummen, COO and General Counsel
12-Lead ECG-Based Mapping Guides Non-Invasive Radiation Therapy
In an abstract published in the American Heart Association’s journal, Circulation, researchers conclude that a case of stereotactic radioablation of ventricular tachycardia illustrates efficacy of non-invasive 12-lead ECG mapping and radioablation in a patient who failed prior invasive VT therapies.
Computerized Mapping Enables New Procedure for Ventricular Fibrillation
A new procedure developed at UC San Diego Health uses targeted ablation to enable treatment for ventricular fibrillation. The procedure is enabled by the use of electrocardiograms to make a computerized map of the heart’s own voltage.
Vektor Medical, Inc. Successfully Closes Its Convertible Note Funding Round
Today, Vektor Medical, Inc. announces the closing of its Convertible Note funding round. The funds will be used to support research relating to and development of a non-invasive computational arrhythmia mapping device. “We’re excited to welcome our investors on board and join Vektor’s journey in creating the next generation of arrhythmia mapping technology. This funding round enables us to build out our team and further research and develop the technology created by our UCSD founders”. Mike Monko, CEO & Co-Founder of Vektor Medical, Inc.